EXEL NASDAQ
Exelixis, Inc.
1W: +1.5%
1M: +12.0%
3M: +18.1%
YTD: +50.0%
1Y: +68.8%
3Y: +209.6%
5Y: +203.9%
$65.35
+0.24 (+0.37%)
Pre-Market: $65.00 (-0.35, -0.54%)
Weekly Expected Move ±2.7%
$61
$63
$65
$66
$68
Credit Risk of going bust: lower than 92% of companies Debt: 1.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.05 (down 99.9%), Exelixis, Inc. would be worth roughly what it owes.
Total debt $165.9M against a stock market value of $16.43B.
Distance to default 15.71 (Merton model): prices to 2026-10-27, balance sheet 2026-07-03, debt counted $83.0M (short-term plus half of long-term), stock volatility 33.8%; Altman Z'' 7.72. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.05 (down 99.9%), Exelixis, Inc. would be worth roughly what it owes.
Total debt $165.9M against a stock market value of $16.43B.
Distance to default 15.71 (Merton model): prices to 2026-10-27, balance sheet 2026-07-03, debt counted $83.0M (short-term plus half of long-term), stock volatility 33.8%; Altman Z'' 7.72. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
#23
of 1060
Biotechnology
Technical Signal Map
27 Bullish
4 Neutral
28 Bearish
EXEL
$16B
Exelixis, Inc.
BULLISH
+91
LZAGY
$54B
Lonza Group AG
BULLISH
+100
ASND
$15B
Ascendis Pharma A/S
BULLISH
+100
HALO
$14B
Halozyme Therapeutics, Inc.
BULLISH
+100
CAI
$9.1B
Caris Life Sciences, Inc.
BULLISH
+100
MANE
$5.8B
Veradermics, Incorporated
BULLISH
+100
REGN
$83B
Regeneron Pharmaceuticals, Inc.
BULLISH
+91
UTHR
$25B
United Therapeutics Corporation
BULLISH
+84
KYMR
$9.1B
Kymera Therapeutics, Inc.
BULLISH
+84
GNMSF
$28B
Genmab A/S
BULLISH
+75
SYRE
$8.3B
Spyre Therapeutics, Inc.
BULLISH
+75
TGTX
$8.3B
TG Therapeutics, Inc.
BULLISH
+75
NBIX
$15B
Neurocrine Biosciences, Inc.
BULLISH
+68
CSLLY
$134B
CSL Limited
BULLISH
+66
LGND
$6.0B
Ligand Pharmaceuticals Incorporated
BULLISH
+66
TECH
$11B
Bio-Techne Corporation
BULLISH
+58
IOVA
$6.4B
Iovance Biotherapeutics, Inc.
BULLISH
+58
KOD
$5.5B
Kodiak Sciences Inc.
BULLISH
+58
MRNA
$80B
Moderna, Inc.
BULLISH
+56
AKBLF
$7.4B
ALK-Abelló A/S
BULLISH
+53
ROIV
$26B
Roivant Sciences Ltd.
BULLISH
+50
BBIO
$13B
BridgeBio Pharma, Inc.
BULLISH
+43
ONC
$40B
BeOne Medicines AG
BULLISH
+42
COGT
$5.4B
Cogent Biosciences, Inc.
BULLISH
+36
VRTX
$133B
Vertex Pharmaceuticals Incorporated
BULLISH
+34
UCBJY
$58B
UCB S.A.
LEAN BULL
+28
PTGX
$9.0B
Protagonist Therapeutics, Inc.
LEAN BULL
+27
AAVXF
$12B
Abivax S.A.
NEUTRAL
+2
BCHMF
$6.8B
Bachem Holding AG
NEUTRAL
+2
TXG
$9.3B
10x Genomics, Inc.
NEUTRAL
+1
RYTM
$6.2B
Rhythm Pharmaceuticals, Inc.
NEUTRAL
-9
ARGX
$55B
argenx SE
LEAN BEAR
-18
HNGZY
$6.9B
Hangzhou Tigermed Consulting Co., Ltd
LEAN BEAR
-20
INCY
$23B
Incyte Corporation
LEAN BEAR
-23
TWST
$9.2B
Twist Bioscience Corporation
LEAN BEAR
-24
WXIBF
$26B
WuXi Biologics (Cayman) Inc.
BEARISH
-35
PRAX
$7.1B
Praxis Precision Medicines, Inc.
BEARISH
-40
PCVX
$9.5B
Vaxcyte, Inc.
BEARISH
-47
ARWR
$8.2B
Arrowhead Pharmaceuticals, Inc.
BEARISH
-49
IONS
$7.1B
Ionis Pharmaceuticals, Inc.
BEARISH
-49
GNNSF
$9.6B
Genscript Biotech Corporation
BEARISH
-53
CGON
$5.5B
CG Oncology Inc.
BEARISH
-58
IVBXF
$20B
Innovent Biologics, Inc.
BEARISH
-59
IMVT
$5.9B
Immunovant, Inc.
BEARISH
-60
RVMDW
$40B
Revolution Medicines, Inc. Warrant
BEARISH
-66
ALNY
$30B
Alnylam Pharmaceuticals, Inc.
BEARISH
-66
KRYS
$9.2B
Krystal Biotech, Inc.
BEARISH
-66
BMRN
$11B
BioMarin Pharmaceutical Inc.
BEARISH
-69
IBRX
$8.7B
ImmunityBio, Inc.
BEARISH
-69
BLTE
$5.9B
Belite Bio, Inc
BEARISH
-78
CYTK
$8.5B
Cytokinetics, Incorporated
BEARISH
-82
RVMD
$40B
Revolution Medicines, Inc.
BEARISH
-84
BNTX
$22B
BioNTech SE
BEARISH
-84
JAZZ
$14B
Jazz Pharmaceuticals plc
BEARISH
-87
MDGL
$10B
Madrigal Pharmaceuticals, Inc.
BEARISH
-87
INSM
$20B
Insmed Incorporated
BEARISH
-91
REGMF
$5.6B
RemeGen Co., Ltd.
BEARISH
-91
SMMT
$12B
Summit Therapeutics Inc.
BEARISH
-100
AXSM
$7.6B
Axsome Therapeutics, Inc.
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| EXEL Exelixis, Inc. | $16B | 19.9 | 44.4 | 69.0 | 33.7 | 9.2 | 8 | BULLISH | 68.8 |
| LZAGY Lonza Group AG | $54B | -412.9 | 13.5 | 10.5 | 17.5 | -9.7 | 8 | BULLISH | 4.3 |
| ASND Ascendis Pharma A/S | $15B | 18.3 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BULLISH | 21.7 |
| HALO Halozyme Therapeutics, Inc. | $14B | 36.5 | 173.7 | 32.5 | 47.8 | 41.2 | 5 | BULLISH | 94.3 |
| CAI Caris Life Sciences, Inc. | $9.1B | 90.5 | 20.1 | 61.1 | -0.2 | 445.5 | 7 | BULLISH | 8.4 |
| MANE Veradermics, Incorporated | $5.8B | — | — | — | — | — | — | BULLISH | — |
| REGN Regeneron Pharmaceuticals, Inc. | $83B | 19.5 | 14.0 | 12.9 | 30.2 | 9.3 | 7 | BULLISH | 41.4 |
| UTHR United Therapeutics Corporation | $25B | 19.6 | 19.3 | 31.3 | 42.5 | 2.5 | 6 | BULLISH | 41.2 |
| KYMR Kymera Therapeutics, Inc. | $9.1B | -36.2 | -24.2 | -30.7 | -94.2 | 134.8 | 6 | BULLISH | 100.8 |
| GNMSF Genmab A/S | $28B | 34.8 | 3.9 | 11.9 | 26.2 | -82.1 | 4 | BULLISH | 47.7 |
| SYRE Spyre Therapeutics, Inc. | $8.3B | -50.8 | -23.0 | 359.8 | — | — | 3 | BULLISH | 323.8 |
| TGTX TG Therapeutics, Inc. | $8.3B | 18.5 | 100.3 | 73.5 | 3.2 | 76.1 | 6 | BULLISH | 69.3 |
| NBIX Neurocrine Biosciences, Inc. | $15B | 20.7 | 22.1 | 16.0 | 15.1 | 34.4 | 6 | BULLISH | 1.4 |
| CSLLY CSL Limited | $134B | -26.1 | -15.2 | 13.1 | -40.2 | 1.7 | 4 | BULLISH | 1.4 |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 31.1 | 22.0 | 11.3 | 76.2 | 54.9 | 5 | BULLISH | 66.7 |
| TECH Bio-Techne Corporation | $11B | 62.1 | 9.0 | 8.9 | 17.0 | -0.4 | 7 | BULLISH | 10.3 |
| IOVA Iovance Biotherapeutics, Inc. | $6.4B | -20.0 | -40.4 | -49.1 | -47.6 | 34.5 | 6 | BULLISH | 548.0 |
| KOD Kodiak Sciences Inc. | $5.5B | -21.8 | -368.4 | -630.1 | — | — | 1 | BULLISH | 388.6 |
| MRNA Moderna, Inc. | $80B | -26.1 | -39.0 | -90.1 | -539.3 | -27.2 | 2 | BULLISH | 724.0 |
| AKBLF ALK-Abelló A/S | $7.4B | 39.9 | 21.2 | 23.9 | 18.9 | 16.4 | 8 | BULLISH | 12.8 |
| ROIV Roivant Sciences Ltd. | $26B | -96.2 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BULLISH | 100.5 |
| BBIO BridgeBio Pharma, Inc. | $13B | -19.4 | 32.4 | 57.9 | -62.5 | 202.4 | 4 | BULLISH | 27.9 |
| ONC BeOne Medicines AG | $40B | 25.9 | 14.7 | 57.2 | 13.9 | 34.3 | 8 | BULLISH | 17.9 |
| COGT Cogent Biosciences, Inc. | $5.4B | -13.9 | -109.7 | 1964.0 | — | — | 3 | BULLISH | 111.6 |
| VRTX Vertex Pharmaceuticals Incorporated | $133B | 30.1 | 23.5 | 28.3 | 33.0 | 10.6 | 6 | BULLISH | 23.6 |
| UCBJY UCB S.A. | $58B | 23.3 | 20.7 | 16.4 | 26.0 | 25.3 | 6 | LEAN BULL | 5.8 |
| PTGX Protagonist Therapeutics, Inc. | $9.0B | 115.9 | 11.0 | 84.1 | 76.3 | 34.8 | 7 | LEAN BULL | 88.5 |
| AAVXF Abivax S.A. | $12B | -17.0 | -221.8 | 440.6 | — | -133.5 | 4 | NEUTRAL | 57.0 |
| BCHMF Bachem Holding AG | $6.8B | 41.9 | 10.6 | 8.2 | 15.4 | 4.3 | 3 | NEUTRAL | 24.7 |
| TXG 10x Genomics, Inc. | $9.3B | -132.2 | -9.4 | -19.8 | -11.9 | -4.3 | 5 | NEUTRAL | 466.6 |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.2B | -29.6 | -200.0 | 144.2 | -69.2 | 53.5 | 4 | NEUTRAL | -16.6 |
| ARGX argenx SE | $55B | 40.9 | 26.0 | 50.1 | 29.8 | 162.5 | 7 | LEAN BEAR | 8.0 |
| HNGZY Hangzhou Tigermed Consulting Co., Ltd | $6.9B | 587.9 | 0.5 | 1.6 | -24.2 | 12.0 | 6 | LEAN BEAR | 11.2 |
| INCY Incyte Corporation | $23B | 14.3 | 30.7 | 82.1 | 35.0 | 26.9 | 8 | LEAN BEAR | 27.7 |
| TWST Twist Bioscience Corporation | $9.2B | -72.0 | -29.6 | -29.2 | -29.6 | 19.2 | 2 | LEAN BEAR | 368.6 |
| WXIBF WuXi Biologics (Cayman) Inc. | $26B | 32.3 | 10.6 | 16.0 | 20.7 | 16.0 | 9 | BEARISH | 20.2 |
| PRAX Praxis Precision Medicines, Inc. | $7.1B | -20.7 | -38.9 | -51.2 | — | -100.0 | 4 | BEARISH | 53.8 |
| PCVX Vaxcyte, Inc. | $9.5B | -7.9 | -36.5 | -66.4 | — | — | 0 | BEARISH | 43.7 |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.2B | -26.4 | -64.8 | 65.7 | -258.2 | 12.2 | 4 | BEARISH | 55.3 |
| IONS Ionis Pharmaceuticals, Inc. | $7.1B | -12.7 | -105.4 | -58.5 | -42.8 | -7.4 | 3 | BEARISH | -38.0 |
| GNNSF Genscript Biotech Corporation | $9.6B | -15.7 | -15.4 | 2.9 | -32.0 | 53.1 | 4 | BEARISH | 97.7 |
| CGON CG Oncology Inc. | $5.5B | -23.3 | -26.4 | -2066.1 | -6832.8 | 1030.3 | 3 | BEARISH | 44.1 |
| IVBXF Innovent Biologics, Inc. | $20B | 99.2 | 6.9 | 67.2 | 14.5 | 35.4 | 6 | BEARISH | -11.4 |
| IMVT Immunovant, Inc. | $5.9B | -10.2 | -80.1 | 707.5 | -2159.6 | — | 2 | BEARISH | 52.5 |
| RVMDW Revolution Medicines, Inc. Warrant | $40B | -21.0 | -79.1 | 186.4 | — | — | 1 | BEARISH | 2251.5 |
| ALNY Alnylam Pharmaceuticals, Inc. | $30B | 37.2 | 100.7 | -152.8 | 12.7 | 95.1 | 6 | BEARISH | -51.1 |
| KRYS Krystal Biotech, Inc. | $9.2B | 38.8 | 20.1 | 40.4 | 45.9 | 22.6 | 7 | BEARISH | 72.2 |
| BMRN BioMarin Pharmaceutical Inc. | $11B | 145.7 | 1.2 | 1.4 | 4.5 | 11.2 | 4 | BEARISH | 1.6 |
| IBRX ImmunityBio, Inc. | $8.7B | -8.9 | 122.7 | 33.7 | -449.6 | 192.9 | 4 | BEARISH | 249.4 |
| BLTE Belite Bio, Inc | $5.9B | -52.8 | -20.8 | -11.5 | — | — | 3 | BEARISH | 57.0 |
| CYTK Cytokinetics, Incorporated | $8.5B | -8.5 | 329.8 | 811.2 | -622.8 | -17.2 | 2 | BEARISH | 6.4 |
| RVMD Revolution Medicines, Inc. | $40B | -21.0 | -79.1 | 186.4 | — | — | 1 | BEARISH | 241.8 |
| BNTX BioNTech SE | $22B | -11.5 | -9.3 | -18.0 | -777.3 | -8.2 | 2 | BEARISH | -17.6 |
| JAZZ Jazz Pharmaceuticals plc | $14B | 13.6 | 22.1 | 26.4 | 16.0 | 12.6 | 8 | BEARISH | 49.3 |
| MDGL Madrigal Pharmaceuticals, Inc. | $10B | -34.2 | -53.3 | -778.9 | -15.9 | 149.0 | 2 | BEARISH | 4.5 |
| INSM Insmed Incorporated | $20B | -23.1 | -87.2 | -364.8 | -3.1 | 185.8 | 5 | BEARISH | -40.5 |
| REGMF RemeGen Co., Ltd. | $5.6B | 9.4 | 108.3 | 139.6 | 83.4 | 283.6 | 7 | BEARISH | -7.7 |
| SMMT Summit Therapeutics Inc. | $12B | -13.7 | -192.5 | 1714.4 | — | — | 3 | BEARISH | -20.5 |
| AXSM Axsome Therapeutics, Inc. | $7.6B | -37.9 | -245.1 | 859.1 | -23.5 | 56.9 | 5 | BEARISH | 9.8 |
| EXEL Exelixis, Inc. | $16B | 19.9 | 44.4 | 69.0 | 33.7 | 9.2 | 8 | BULLISH | 68.8 |
| CRL Charles River Laboratories International, Inc. | $17B | -74.1 | -7.7 | 6.9 | -0.1 | -0.7 | 4 | BULLISH | 82.2 |
| MEDP Medpace Holdings, Inc. | $19B | 36.7 | 117.9 | 1953.7 | 19.2 | 20.4 | 9 | BULLISH | 11.3 |
| PMCUF Pro Medicus Limited | $13B | 77.4 | 75.0 | 68.1 | 68.7 | 22.8 | 7 | BULLISH | -33.0 |
| CLPBY Coloplast A/S | $17B | 38.9 | 18.5 | 70.9 | 19.9 | -2.9 | 5 | BULLISH | -23.4 |
| SNN Smith & Nephew plc | $13B | 19.6 | 11.8 | 9.9 | 9.8 | 5.3 | 7 | BULLISH | -15.5 |
| ICLR ICON Public Limited Company | $14B | 42.6 | 3.5 | 5.5 | 3.5 | 2.0 | 6 | BULLISH | 2.7 |
| ZBH Zimmer Biomet Holdings, Inc. | $19B | 23.3 | 6.4 | 5.9 | 9.1 | 8.6 | 6 | BULLISH | -6.8 |
| SAUHY Straumann Holding AG | $19B | 41.9 | 17.3 | 21.7 | 18.1 | 3.0 | 6 | BULLISH | 4.9 |
| RVTY Revvity, Inc. | $18B | 77.1 | 3.2 | 3.5 | 7.1 | 5.5 | 6 | BULLISH | 63.7 |
| BAX Baxter International Inc. | $13B | -12.2 | -15.7 | -1.6 | 4.3 | 5.4 | 3 | BULLISH | 8.4 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $16B | 59.5 | 23.3 | 27.3 | 20.6 | 5.0 | 6 | BULLISH | 34.9 |
| SGIOY Shionogi & Co., Ltd. | $16B | 9.7 | 13.6 | 9.9 | 50.6 | 10.3 | 5 | BULLISH | 20.6 |
| ERFSF Eurofins Scientific SE | $17B | 28.5 | 12.8 | 4.6 | 8.2 | 3.3 | 6 | BULLISH | 25.6 |
| BIOVF Swedish Orphan Biovitrum AB | $16B | 116.9 | 3.4 | 17.2 | 14.0 | 13.3 | 4 | LEAN BULL | 37.3 |
| JDHIY JD Health International Inc. | $16B | 16.3 | 10.3 | 31.0 | 8.4 | 19.6 | 6 | LEAN BULL | -43.9 |
| CHJTF CSPC Pharmaceutical Group Limited | $14B | 10.4 | 20.7 | 36.7 | 32.8 | 88.1 | 6 | NEUTRAL | 13.3 |
| IHHHF IHH Healthcare Berhad | $15B | 30.7 | 7.3 | 6.1 | 8.1 | 7.1 | 5 | NEUTRAL | 43.7 |
| SUVPF Sartorius AG | $19B | 92.0 | 7.7 | 6.7 | 7.1 | 3.6 | 7 | LEAN BEAR | -0.5 |
| SOLV Solventum Corporation | $15B | 10.1 | 34.0 | 18.1 | 4.2 | -0.9 | 7 | BEARISH | 16.2 |
| GIKLY Grifols, S.A. | $15B | 15.9 | 8.4 | 7.4 | 8.2 | -0.2 | 6 | BEARISH | -19.0 |
| EXEL Exelixis, Inc. | $16B | 19.9 | 44.4 | 69.0 | 33.7 | 9.2 | 8 | BULLISH | 68.8 |
| ABBV AbbVie Inc. | $505B | 80.7 | -206.4 | 23.5 | 21.3 | 10.4 | 7 | BULLISH | 25.6 |
| TKPHF Takeda Pharmaceutical Company Limited | $66B | 55.3 | 2.5 | 2.8 | 9.3 | 3.3 | 6 | BULLISH | 41.6 |
| LZAGY Lonza Group AG | $54B | -412.9 | 13.5 | 10.5 | 17.5 | -9.7 | 8 | BULLISH | 4.3 |
| RPRX Royalty Pharma plc | $28B | 27.1 | 12.4 | 10.6 | 2.7 | 10.0 | 6 | BULLISH | 76.2 |
| WST West Pharmaceutical Services, Inc. | $28B | 50.6 | 19.1 | 19.0 | 17.7 | 12.4 | 9 | BULLISH | 34.0 |
| LH Labcorp Holdings Inc. | $27B | 27.2 | 11.7 | 8.6 | 8.0 | 6.4 | 8 | BULLISH | 19.8 |
| MEDP Medpace Holdings, Inc. | $19B | 36.7 | 117.9 | 1953.7 | 19.2 | 20.4 | 9 | BULLISH | 11.3 |
| CRL Charles River Laboratories International, Inc. | $17B | -74.1 | -7.7 | 6.9 | -0.1 | -0.7 | 4 | BULLISH | 82.2 |
| ASND Ascendis Pharma A/S | $15B | 18.3 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BULLISH | 21.7 |
| HALO Halozyme Therapeutics, Inc. | $14B | 36.5 | 173.7 | 32.5 | 47.8 | 41.2 | 5 | BULLISH | 94.3 |
| QGEN Qiagen N.V. | $10B | 25.7 | 11.9 | 11.2 | 19.3 | 3.0 | 8 | BULLISH | 1.7 |
| CAI Caris Life Sciences, Inc. | $9.1B | 90.5 | 20.1 | 61.1 | -0.2 | 445.5 | 7 | BULLISH | 8.4 |
| MANE Veradermics, Incorporated | $5.8B | — | — | — | — | — | — | BULLISH | — |
| JNJ Johnson & Johnson | $636B | 40.7 | 20.0 | 21.3 | 0.8 | 7.8 | 6 | BULLISH | 42.0 |
| TMO Thermo Fisher Scientific Inc. | $249B | 36.5 | 13.4 | 8.6 | 14.2 | 8.3 | 8 | BULLISH | 21.2 |
| DHR Danaher Corporation | $162B | 37.9 | 8.3 | 6.3 | 18.8 | 5.5 | 7 | BULLISH | 4.8 |
| MDT Medtronic Plc | $122B | 23.0 | 10.7 | 7.8 | 15.1 | 9.8 | 9 | BULLISH | 3.6 |
| REGN Regeneron Pharmaceuticals, Inc. | $83B | 19.5 | 14.0 | 12.9 | 30.2 | 9.3 | 7 | BULLISH | 41.4 |
| CI Cigna Corporation | $81B | 12.3 | 15.5 | 11.8 | 2.3 | 7.7 | 8 | BULLISH | -0.6 |
| EW Edwards Lifesciences Corporation | $51B | 52.2 | 9.5 | 17.9 | 13.9 | 14.6 | 6 | BULLISH | 19.3 |
| SDZNY Sandoz Group AG | $42B | 66.4 | 7.2 | 10.1 | 1.9 | 29.1 | 6 | BULLISH | 59.1 |
| ILMN Illumina, Inc. | $41B | 51.7 | 32.4 | 18.2 | 17.9 | 4.9 | 7 | BULLISH | 179.2 |
| MTD Mettler-Toledo International Inc. | $33B | 37.8 | -736.4 | 46.7 | 22.7 | 6.9 | 8 | BULLISH | 17.5 |
| ORINY Orion Oyj | $30B | 23.0 | 53.6 | 46.3 | 26.9 | 22.6 | 7 | BULLISH | 44.0 |
| PMCUF Pro Medicus Limited | $13B | 77.4 | 75.0 | 68.1 | 68.7 | 22.8 | 7 | BULLISH | -33.0 |
| AVTR Avantor, Inc. | $12B | -20.4 | -9.7 | -2.5 | 2.3 | -1.6 | 6 | BULLISH | 11.1 |
| GKOS Glaukos Corporation | $11B | -55.7 | -26.0 | -12.7 | -9.9 | 41.5 | 3 | BULLISH | 142.7 |
| GEHC GE HealthCare Technologies Inc. | $32B | 20.4 | 15.4 | 10.6 | 10.8 | 1.4 | 5 | BULLISH | -9.0 |
| ABT Abbott Laboratories | $179B | 38.2 | 10.7 | 7.3 | 7.4 | 8.1 | 5 | BULLISH | -18.7 |
| SNY Sanofi | $100B | 23.0 | 5.7 | 6.4 | 2.8 | 13.4 | 6 | BULLISH | -18.9 |
| UTHR United Therapeutics Corporation | $25B | 19.6 | 19.3 | 31.3 | 42.5 | 2.5 | 6 | BULLISH | 41.2 |
| GH Guardant Health, Inc. | $23B | -51.0 | 171.6 | -88.3 | -35.9 | 42.7 | 6 | BULLISH | 146.8 |
| RDY Dr. Reddy's Laboratories Limited | $11B | 39.1 | 7.5 | 6.0 | 10.7 | -3.1 | 4 | BULLISH | -5.7 |
| PODD Insulet Corp. | $10B | 28.0 | 26.0 | 21.3 | 11.8 | 29.4 | 9 | BULLISH | -53.3 |
| KYMR Kymera Therapeutics, Inc. | $9.1B | -36.2 | -24.2 | -30.7 | -94.2 | 134.8 | 6 | BULLISH | 100.8 |
| PFE Pfizer Inc. | $171B | 39.4 | 5.0 | 11.3 | -1.6 | -0.2 | 7 | BULLISH | 22.5 |
| MCK McKesson Corporation | $117B | 25.8 | -148.0 | 237.7 | 0.6 | 8.8 | 8 | BULLISH | 20.7 |
| WILYY Demant A/S | $12B | 46.8 | 15.9 | 10.9 | 9.1 | 10.6 | 5 | BULLISH | 47.3 |
| NTRA Natera, Inc. | $58B | -302.1 | -12.5 | -23.6 | -8.9 | 37.8 | 6 | BULLISH | 113.4 |
| IDXX IDEXX Laboratories, Inc. | $44B | 39.4 | 74.2 | 46.5 | 27.8 | 12.8 | 9 | BULLISH | -12.4 |
| ZTS Zoetis Inc. | $33B | 12.9 | 64.4 | 26.3 | 28.0 | 1.4 | 6 | BULLISH | -46.2 |
| CLPBY Coloplast A/S | $17B | 38.9 | 18.5 | 70.9 | 19.9 | -2.9 | 5 | BULLISH | -23.4 |
| SNN Smith & Nephew plc | $13B | 19.6 | 11.8 | 9.9 | 9.8 | 5.3 | 7 | BULLISH | -15.5 |
| PEN Penumbra, Inc. | $13B | 79.2 | 11.4 | 13.6 | 8.9 | 17.6 | 6 | BULLISH | 28.1 |
| COO The Cooper Companies, Inc. | $12B | 20.4 | 6.8 | 6.3 | 40.6 | 4.7 | 6 | BULLISH | -18.5 |
| RHHBF Roche Holding AG | $393B | 26.0 | 40.2 | 24.6 | 22.6 | 27.8 | 6 | BULLISH | 30.5 |
| NVS Novartis AG | $287B | 23.6 | 30.6 | 16.8 | 22.7 | 0.8 | 5 | BULLISH | 20.3 |
| GILD Gilead Sciences, Inc. | $193B | -61.2 | -20.6 | -3.4 | -134.5 | 5.5 | 5 | BULLISH | 32.4 |
| ISRG Intuitive Surgical, Inc. | $160B | 53.3 | 18.0 | 22.6 | 17.1 | 20.5 | 7 | BULLISH | -18.4 |
| CVS CVS Health Corp. | $120B | 23.8 | 6.2 | 4.9 | 2.8 | 7.4 | 8 | BULLISH | 11.2 |
| SYK Stryker Corporation | $118B | 31.0 | 16.5 | 11.6 | 19.4 | 8.5 | 9 | BULLISH | -21.0 |
| SOAGY Sartorius AG ADR | $92B | 92.0 | 7.7 | 6.6 | 7.1 | 4.3 | 7 | BULLISH | 16.0 |
| WAT Waters Corporation | $45B | 116.6 | 1.9 | 1.5 | -8.3 | 52.5 | 5 | BULLISH | 30.3 |
| BIIB Biogen Inc. | $37B | 44.5 | 4.6 | 4.8 | 3.6 | -0.5 | 3 | BULLISH | 68.6 |
| GNMSF Genmab A/S | $28B | 34.8 | 3.9 | 11.9 | 26.2 | -82.1 | 4 | BULLISH | 47.7 |
| VTRS Viatris Inc. | $21B | -52.0 | -2.8 | -0.3 | -3.2 | 4.4 | 7 | BULLISH | 83.0 |
| ALGN Align Technology, Inc. | $11B | 26.4 | 10.2 | 12.3 | 10.3 | 4.4 | 7 | BULLISH | 12.4 |
| SYRE Spyre Therapeutics, Inc. | $8.3B | -50.8 | -23.0 | 359.8 | — | — | 3 | BULLISH | 323.8 |
| TGTX TG Therapeutics, Inc. | $8.3B | 18.5 | 100.3 | 73.5 | 3.2 | 76.1 | 6 | BULLISH | 69.3 |
| CHGCF Chugai Pharmaceutical Co., Ltd. | $74B | 23.3 | 23.7 | 45.1 | 34.1 | 12.6 | 6 | BULLISH | -0.7 |
| NBIX Neurocrine Biosciences, Inc. | $15B | 20.7 | 22.1 | 16.0 | 15.1 | 34.4 | 6 | BULLISH | 1.4 |
| LLY Eli Lilly and Company | $1.2T | 42.9 | 102.4 | 39.2 | 30.9 | 49.6 | 9 | BULLISH | 55.5 |
| AMGN Amgen Inc. | $237B | 27.6 | 91.5 | 19.5 | 23.6 | 9.2 | 8 | BULLISH | 57.8 |
| CSLLY CSL Limited | $134B | -26.1 | -15.2 | 13.1 | -40.2 | 1.7 | 4 | BULLISH | 1.4 |
| CAH Cardinal Health, Inc. | $58B | 33.9 | -60.5 | 92.8 | 0.6 | 14.2 | 8 | BULLISH | 53.7 |
| BDX Becton, Dickinson and Company | $54B | 58.7 | 3.8 | 4.1 | 7.6 | -2.6 | 6 | BULLISH | 5.5 |
| A Agilent Technologies, Inc. | $49B | 34.9 | 21.0 | 14.9 | 19.3 | 8.6 | 7 | BULLISH | 19.9 |
| IQV IQVIA Holdings Inc. | $46B | 32.6 | 21.7 | 33.3 | 7.9 | 8.8 | 9 | BULLISH | 23.1 |
| OTSKY Otsuka Holdings Co., Ltd. | $42B | 15.9 | 13.8 | 12.2 | 16.7 | 10.9 | 8 | BULLISH | 44.2 |
| TRUMY Terumo Corporation | $22B | 21.2 | 11.0 | 9.6 | 22.6 | 15.6 | 5 | BULLISH | -8.6 |
| SONVF Sonova Holding AG | $20B | 38.9 | 20.4 | 17.2 | 19.7 | -7.1 | 6 | BULLISH | 22.9 |
| ZBH Zimmer Biomet Holdings, Inc. | $19B | 23.3 | 6.4 | 5.9 | 9.1 | 8.6 | 6 | BULLISH | -6.8 |
| ICLR ICON Public Limited Company | $14B | 42.6 | 3.5 | 5.5 | 3.5 | 2.0 | 6 | BULLISH | 2.7 |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 31.1 | 22.0 | 11.3 | 76.2 | 54.9 | 5 | BULLISH | 66.7 |
| FSNUY Fresenius SE & Co. KGaA | $117B | 16.8 | 8.1 | 5.6 | 6.4 | 5.9 | 7 | BULLISH | -20.4 |
| GSK GSK plc | $102B | 16.0 | 25.5 | 18.8 | 5.2 | 5.0 | 7 | BULLISH | 18.9 |
| SEMHF Siemens Healthineers AG | $53B | 21.1 | 12.1 | 8.4 | 11.6 | 10.0 | 9 | BULLISH | -17.9 |
| DGX Quest Diagnostics Incorporated | $27B | 23.8 | 15.2 | 10.2 | 10.1 | 9.1 | 8 | BULLISH | 33.1 |
| SAUHY Straumann Holding AG | $19B | 41.9 | 17.3 | 21.7 | 18.1 | 3.0 | 6 | BULLISH | 4.9 |
| CNC Centene Corp. | $35B | 23.2 | 6.8 | 6.4 | -0.1 | 4.8 | 7 | BULLISH | 101.6 |
| RVTY Revvity, Inc. | $18B | 77.1 | 3.2 | 3.5 | 7.1 | 5.5 | 6 | BULLISH | 63.7 |
| BAX Baxter International Inc. | $13B | -12.2 | -15.7 | -1.6 | 4.3 | 5.4 | 3 | BULLISH | 8.4 |
| TECH Bio-Techne Corporation | $11B | 62.1 | 9.0 | 8.9 | 17.0 | -0.4 | 7 | BULLISH | 10.3 |
| IOVA Iovance Biotherapeutics, Inc. | $6.4B | -20.0 | -40.4 | -49.1 | -47.6 | 34.5 | 6 | BULLISH | 548.0 |
| KOD Kodiak Sciences Inc. | $5.5B | -21.8 | -368.4 | -630.1 | — | — | 1 | BULLISH | 388.6 |
| MRNA Moderna, Inc. | $80B | -26.1 | -39.0 | -90.1 | -539.3 | -27.2 | 2 | BULLISH | 724.0 |
| HOCPY HOYA Corporation | $56B | 33.3 | 27.3 | 46.1 | 25.7 | 14.2 | 6 | BULLISH | 12.2 |
| HLN Haleon plc | $45B | 20.7 | 10.1 | 8.4 | 13.6 | 1.3 | 8 | BULLISH | 8.9 |
| ALC Alcon Inc. | $34B | 53.4 | 2.9 | 3.6 | 0.0 | 7.8 | 6 | BULLISH | -8.8 |
| PHG Koninklijke Philips N.V. | $26B | 20.3 | 10.2 | 7.6 | 8.8 | -1.1 | 6 | BULLISH | -8.4 |
| STE STERIS plc | $23B | 27.9 | 11.4 | 9.7 | 13.4 | 8.4 | 8 | BULLISH | -4.9 |
| AKBLF ALK-Abelló A/S | $7.4B | 39.9 | 21.2 | 23.9 | 18.9 | 16.4 | 8 | BULLISH | 12.8 |
| SRTOY Sartorius Stedim Biotech S.A. | $228B | 66.4 | 7.4 | 6.2 | 12.5 | 4.4 | 8 | BULLISH | -0.5 |
| ESLOF EssilorLuxottica S.A. | $94B | 33.7 | 6.5 | 5.2 | 10.6 | 7.4 | 6 | BULLISH | -44.5 |
| BSX Boston Scientific Corporation | $66B | 18.2 | 15.5 | 11.6 | 16.7 | 13.5 | 8 | BULLISH | -55.4 |
| ROIV Roivant Sciences Ltd. | $26B | -96.2 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BULLISH | 100.5 |
| BMXXY bioMérieux S.A. | $12B | 22.8 | 11.2 | 8.9 | 11.5 | -3.5 | 7 | BULLISH | -28.0 |
| GMED Globus Medical, Inc. | $11B | 20.4 | 11.8 | 12.3 | 19.2 | 19.7 | 8 | BULLISH | 29.8 |
| ELV Elevance Health Inc. | $95B | 18.0 | 11.6 | 16.2 | 2.7 | 3.6 | 7 | BULLISH | 23.7 |
| TEVA Teva Pharmaceutical Industries Limited | $46B | 64.1 | 9.7 | 9.3 | -13.9 | 4.1 | 7 | BULLISH | 113.2 |
| BBIO BridgeBio Pharma, Inc. | $13B | -19.4 | 32.4 | 57.9 | -62.5 | 202.4 | 4 | BULLISH | 27.9 |
| ONC BeOne Medicines AG | $40B | 25.9 | 14.7 | 57.2 | 13.9 | 34.3 | 8 | BULLISH | 17.9 |
| UNH UnitedHealth Group Incorporated | $375B | 23.4 | 15.9 | 13.5 | 3.6 | 3.3 | 7 | BULLISH | 14.0 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $16B | 59.5 | 23.3 | 27.3 | 20.6 | 5.0 | 6 | BULLISH | 34.9 |
| COGT Cogent Biosciences, Inc. | $5.4B | -13.9 | -109.7 | 1964.0 | — | — | 3 | BULLISH | 111.6 |
| RCDTF Recordati Industria Chimica e Farmaceutica S.p.A. | $12B | 21.7 | 24.9 | 15.4 | 16.7 | 9.2 | 7 | BULLISH | -9.2 |
| VRTX Vertex Pharmaceuticals Incorporated | $133B | 30.1 | 23.5 | 28.3 | 33.0 | 10.6 | 6 | BULLISH | 23.6 |
| SGIOY Shionogi & Co., Ltd. | $16B | 9.7 | 13.6 | 9.9 | 50.6 | 10.3 | 5 | BULLISH | 20.6 |
| ERFSF Eurofins Scientific SE | $17B | 28.5 | 12.8 | 4.6 | 8.2 | 3.3 | 6 | BULLISH | 25.6 |
| HUM Humana Inc. | $51B | 39.0 | 6.8 | 17.2 | 1.7 | 18.3 | 4 | BULLISH | 42.7 |
| UCBJY UCB S.A. | $58B | 23.3 | 20.7 | 16.4 | 26.0 | 25.3 | 6 | LEAN BULL | 5.8 |
| BIOVF Swedish Orphan Biovitrum AB | $16B | 116.9 | 3.4 | 17.2 | 14.0 | 13.3 | 4 | LEAN BULL | 37.3 |
| PTGX Protagonist Therapeutics, Inc. | $9.0B | 115.9 | 11.0 | 84.1 | 76.3 | 34.8 | 7 | LEAN BULL | 88.5 |
| AZN AstraZeneca PLC | $266B | 25.4 | 22.0 | 15.0 | 16.3 | 8.6 | 9 | LEAN BULL | 4.5 |
| IPSEY Ipsen S.A. | $58B | 24.6 | 11.5 | 16.3 | 18.2 | 8.0 | 6 | LEAN BULL | 22.7 |
| BMY Bristol-Myers Squibb Company | $126B | 13.6 | 46.7 | 17.8 | 25.6 | 3.1 | 8 | LEAN BULL | 46.8 |
| MKGAF Merck KGaA | $70B | 26.5 | 8.1 | 8.1 | 9.0 | -0.4 | 7 | LEAN BULL | 19.4 |
| ALPMF Astellas Pharma Inc. | $30B | 12.3 | 21.4 | 16.9 | 22.1 | 17.3 | 7 | LEAN BULL | 60.4 |
| JDHIY JD Health International Inc. | $16B | 16.3 | 10.3 | 31.0 | 8.4 | 19.6 | 6 | LEAN BULL | -43.9 |
| TEM Tempus AI, Inc. | $12B | -50.5 | -67.4 | -19.8 | 1.5 | 50.4 | 4 | LEAN BULL | -19.1 |
| FMS Fresenius Medical Care AG & Co. KGaA | $12B | 12.2 | 7.3 | 6.7 | 4.5 | -0.5 | 7 | NEUTRAL | -17.4 |
| COR Cencora, Inc. | $63B | 24.1 | 104.3 | 26.5 | 0.9 | 5.1 | 7 | NEUTRAL | -2.0 |
| HCA HCA Healthcare, Inc. | $102B | 54.6 | -124.7 | 23.3 | 8.4 | 7.3 | 6 | NEUTRAL | 0.8 |
| AAVXF Abivax S.A. | $12B | -17.0 | -221.8 | 440.6 | — | -133.5 | 4 | NEUTRAL | 57.0 |
| BCHMF Bachem Holding AG | $6.8B | 41.9 | 10.6 | 8.2 | 15.4 | 4.3 | 3 | NEUTRAL | 24.7 |
| CHJTF CSPC Pharmaceutical Group Limited | $14B | 10.4 | 20.7 | 36.7 | 32.8 | 88.1 | 6 | NEUTRAL | 13.3 |
| TXG 10x Genomics, Inc. | $9.3B | -132.2 | -9.4 | -19.8 | -11.9 | -4.3 | 5 | NEUTRAL | 466.6 |
| DVA DaVita Inc. | $12B | 15.6 | -149.4 | 17.9 | 7.5 | 6.4 | 8 | NEUTRAL | 40.7 |
| NONOF Novo Nordisk A/S | $172B | 9.9 | 59.8 | 35.2 | 26.7 | 5.6 | 5 | NEUTRAL | -28.1 |
| IHHHF IHH Healthcare Berhad | $15B | 30.7 | 7.3 | 6.1 | 8.1 | 7.1 | 5 | NEUTRAL | 43.7 |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.2B | -29.6 | -200.0 | 144.2 | -69.2 | 53.5 | 4 | NEUTRAL | -16.6 |
| BAYRY Bayer AG | $48B | -26.2 | -5.5 | 6.4 | 2.0 | -1.5 | 4 | LEAN BEAR | 59.6 |
| SUVPF Sartorius AG | $19B | 92.0 | 7.7 | 6.7 | 7.1 | 3.6 | 7 | LEAN BEAR | -0.5 |
| ARGX argenx SE | $55B | 40.9 | 26.0 | 50.1 | 29.8 | 162.5 | 7 | LEAN BEAR | 8.0 |
| MOH Molina Healthcare, Inc. | $11B | -327.0 | -1.2 | -44.2 | 0.4 | -2.1 | 5 | LEAN BEAR | 22.1 |
| HNGZY Hangzhou Tigermed Consulting Co., Ltd | $6.9B | 587.9 | 0.5 | 1.6 | -24.2 | 12.0 | 6 | LEAN BEAR | 11.2 |
| INCY Incyte Corporation | $23B | 14.3 | 30.7 | 82.1 | 35.0 | 26.9 | 8 | LEAN BEAR | 27.7 |
| TWST Twist Bioscience Corporation | $9.2B | -72.0 | -29.6 | -29.2 | -29.6 | 19.2 | 2 | LEAN BEAR | 368.6 |
| DSNKY Daiichi Sankyo Company, Limited | $33B | 19.5 | 15.1 | 12.5 | 11.9 | 17.4 | 5 | LEAN BEAR | -37.5 |
| BTSG BrightSpring Health Services, Inc. Common Stock | $12B | 40.8 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | LEAN BEAR | 74.0 |
| WXIBF WuXi Biologics (Cayman) Inc. | $26B | 32.3 | 10.6 | 16.0 | 20.7 | 16.0 | 9 | BEARISH | 20.2 |
| EHC Encompass Health Corporation | $12B | 19.5 | 25.5 | 16.7 | 9.6 | 9.5 | 9 | BEARISH | -3.7 |
| PRAX Praxis Precision Medicines, Inc. | $7.1B | -20.7 | -38.9 | -51.2 | — | -100.0 | 4 | BEARISH | 53.8 |
| RSMDF ResMed Inc. | $36B | 24.0 | 24.3 | 25.3 | 26.2 | 9.9 | 7 | BEARISH | -15.5 |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | $12B | 40.8 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | BEARISH | 68.8 |
| UHS Universal Health Services, Inc. | $11B | 7.4 | 21.0 | 12.5 | 7.7 | 10.0 | 8 | BEARISH | -15.7 |
| PCVX Vaxcyte, Inc. | $9.5B | -7.9 | -36.5 | -66.4 | — | — | 0 | BEARISH | 43.7 |
| RGEN Repligen Corporation | $11B | -837.1 | -0.6 | -1.4 | -18.4 | 13.8 | 4 | BEARISH | 5.7 |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.2B | -26.4 | -64.8 | 65.7 | -258.2 | 12.2 | 4 | BEARISH | 55.3 |
| IONS Ionis Pharmaceuticals, Inc. | $7.1B | -12.7 | -105.4 | -58.5 | -42.8 | -7.4 | 3 | BEARISH | -38.0 |
| SOLV Solventum Corporation | $15B | 10.1 | 34.0 | 18.1 | 4.2 | -0.9 | 7 | BEARISH | 16.2 |
| THC Tenet Healthcare Corporation | $22B | 10.0 | 53.3 | 19.1 | 14.7 | 5.4 | 7 | BEARISH | 24.5 |
| OCPNF Olympus Corporation | $12B | 24.7 | 10.6 | 12.7 | 7.9 | 7.8 | 5 | BEARISH | -9.8 |
| GNNSF Genscript Biotech Corporation | $9.6B | -15.7 | -15.4 | 2.9 | -32.0 | 53.1 | 4 | BEARISH | 97.7 |
| CGON CG Oncology Inc. | $5.5B | -23.3 | -26.4 | -2066.1 | -6832.8 | 1030.3 | 3 | BEARISH | 44.1 |
| IVBXF Innovent Biologics, Inc. | $20B | 99.2 | 6.9 | 67.2 | 14.5 | 35.4 | 6 | BEARISH | -11.4 |
| IMVT Immunovant, Inc. | $5.9B | -10.2 | -80.1 | 707.5 | -2159.6 | — | 2 | BEARISH | 52.5 |
| ELAN Elanco Animal Health Incorporated | $11B | -55.2 | -3.0 | 3.7 | 3.9 | 12.0 | 5 | BEARISH | 2.7 |
| RVMDW Revolution Medicines, Inc. Warrant | $40B | -21.0 | -79.1 | 186.4 | — | — | 1 | BEARISH | 2251.5 |
| ALNY Alnylam Pharmaceuticals, Inc. | $30B | 37.2 | 100.7 | -152.8 | 12.7 | 95.1 | 6 | BEARISH | -51.1 |
| ENSG The Ensign Group, Inc. | $10B | 24.5 | 17.0 | 8.1 | 6.9 | 18.9 | 7 | BEARISH | -8.9 |
| KRYS Krystal Biotech, Inc. | $9.2B | 38.8 | 20.1 | 40.4 | 45.9 | 22.6 | 7 | BEARISH | 72.2 |
| MRK Merck & Co., Inc. | $358B | 112.6 | 7.0 | 6.1 | -8.0 | 4.5 | 4 | BEARISH | 63.5 |
| BMRN BioMarin Pharmaceutical Inc. | $11B | 145.7 | 1.2 | 1.4 | 4.5 | 11.2 | 4 | BEARISH | 1.6 |
| IBRX ImmunityBio, Inc. | $8.7B | -8.9 | 122.7 | 33.7 | -449.6 | 192.9 | 4 | BEARISH | 249.4 |
| WUXAY WuXi AppTec Co., Ltd. | $68B | 15.7 | 30.2 | 35.4 | 39.1 | 25.0 | 8 | BEARISH | 66.6 |
| DXCM DexCom, Inc. | $29B | 30.3 | 38.5 | 42.9 | 19.0 | 15.5 | 9 | BEARISH | 11.7 |
| BLTE Belite Bio, Inc | $5.9B | -52.8 | -20.8 | -11.5 | — | — | 3 | BEARISH | 57.0 |
| CYTK Cytokinetics, Incorporated | $8.5B | -8.5 | 329.8 | 811.2 | -622.8 | -17.2 | 2 | BEARISH | 6.4 |
| RVMD Revolution Medicines, Inc. | $40B | -21.0 | -79.1 | 186.4 | — | — | 1 | BEARISH | 241.8 |
| BNTX BioNTech SE | $22B | -11.5 | -9.3 | -18.0 | -777.3 | -8.2 | 2 | BEARISH | -17.6 |
| JAZZ Jazz Pharmaceuticals plc | $14B | 13.6 | 22.1 | 26.4 | 16.0 | 12.6 | 8 | BEARISH | 49.3 |
| MDGL Madrigal Pharmaceuticals, Inc. | $10B | -34.2 | -53.3 | -778.9 | -15.9 | 149.0 | 2 | BEARISH | 4.5 |
| INSM Insmed Incorporated | $20B | -23.1 | -87.2 | -364.8 | -3.1 | 185.8 | 5 | BEARISH | -40.5 |
| GIKLY Grifols, S.A. | $15B | 15.9 | 8.4 | 7.4 | 8.2 | -0.2 | 6 | BEARISH | -19.0 |
| REGMF RemeGen Co., Ltd. | $5.6B | 9.4 | 108.3 | 139.6 | 83.4 | 283.6 | 7 | BEARISH | -7.7 |
| MDLN Medline Inc. | $30B | 37.7 | 3.2 | 4.4 | 0.8 | — | 4 | BEARISH | — |
| SMMT Summit Therapeutics Inc. | $12B | -13.7 | -192.5 | 1714.4 | — | — | 3 | BEARISH | -20.5 |
| SBMFF Sino Biopharmaceutical Limited | $12B | 30.9 | 21.1 | 40.0 | 17.7 | 28.2 | 7 | BEARISH | -22.9 |
| AXSM Axsome Therapeutics, Inc. | $7.6B | -37.9 | -245.1 | 859.1 | -23.5 | 56.9 | 5 | BEARISH | 9.8 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
EXEL vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F